Progress in research on prevention and treatment of hemophilia inhibitors
- Author:
Shanxi LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: Bypass for homeostasis; Hemophilia; Immune tolerance; Inhibitor; New homeostatic agent
- From: Journal of Xi'an Jiaotong University(Medical Sciences) 2020;41(4):624-627
- CountryChina
- Language:Chinese
- Abstract: Hemophilia F/F inhibitor is a kind of specific neutralizing antibody, making treatment invalid, and increasing bleeding and the incidence of death and disability. It is a serious complication of hemophilia and also a new challenge. Risk factors associated with the production of inhibitors are related to genetic factors and the environment, providing a direction for prevention. The existing effective treatments of hemophilia inhibitor include bypass drugs for homeostasis and immune tolerance induction therapy to clear inhibitor and new homeostatic prophylaxis. However, these treatment still cannot meet the needs. Recently, a variety of new hemostatic drugs have been developed, which have a long half-life and can be injected subcutaneously once every four weeks for prevention and treatment. The annual bleeding rate is 0 and no inhibitor is produced, which has made a breakthrough.
